Logo
x

Search

Subscribe Now

accelerated approval

Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer

Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Me...

  • September 22, 2021
BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma

BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma

  • September 15, 2021
GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Accelerated Approval for the Treatment of dMMR Recurrent or Advanced Solid Tumors

GSK's Jemperli (dostarlimab-gxly) Receives the US FDA's Accelerated Approval for the Treatment of dMMR Recurrent or Advanced Solid...

  • August 18, 2021
Biogen and Eisai's Aduhelm (aducanumab-avwa) Receive the US FDA's Accelerated Approval for Alzheimer Disease

Biogen and Eisai's Aduhelm (aducanumab-avwa) Receive the US FDA's Accelerated Approval for Alzheimer Disease

  • June 8, 2021
Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

Epizyme's Tazverik (tazemetostat) Receives the US FDA's Accelerated Approval as the First Therapy for Epithelioid Sarcoma

  • January 24, 2020
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Receive the FDA's Accelerated Approval for HER-2 Positive Unresectable/ Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Receive the FDA's Accelerated Approval for HER-2 Positive Unrese...

  • December 26, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.